TY - JOUR
T1 - Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria
T2 - Effect of angiotensin II blockade
AU - Ihara, Genei
AU - Kiyomoto, Hideyasu
AU - Kobori, Hiroyuki
AU - Nagai, Yukiko
AU - Ohashi, Naro
AU - Hitomi, Hirofumi
AU - Nakano, Daisuke
AU - Pelisch, Nicolas
AU - Hara, Taiga
AU - Mori, Takefumi
AU - Ito, Sadayoshi
AU - Kohno, Masakazu
AU - Nishiyama, Akira
PY - 2010/11
Y1 - 2010/11
N2 - Objective: Clinical studies indicate that the remission, regression or both of nephrotic-range albuminuria are exerted by angiotensin II receptor blockers (ARBs) in diabetes. The current study was performed to test the hypothesis that these effects of ARBs are associated with regression of glomerular podocyte injury. Methods: We examined the effects of an ARB, olmesartan, on glomerular podocyte injury in type 2 diabetic Otsuka-Long-Evans-Tokushima-Fatty rats with overt albuminuria. Results: At baseline (55-week-old), diabetic Otsuka-Long-Evans-Tokushima-Fatty rats showed severe albuminuria with desmin-positive areas (an index of podocyte injury) in both superficial and juxtamedullary glomeruli, and podocyte injury was much greater in juxtamedullary than in superficial glomeruli. At 75-week-old, Otsuka-Long-Evans-Tokushima- Fatty rats had developed more severe albuminuria and superficial glomerular podocyte injury, whereas juxtamedullary glomerular podocyte injury did not advance further. Olmesartan (10 mg/kg per day) decreased albuminuria and superficial glomerular desmin staining to levels that were lower than those at baseline, whereas advanced juxtamedullary glomerular podocyte injury was not changed. Conclusion: The current study demonstrates for the first time that juxtamedullary glomerular podocyte injury reaches a severe condition at an earlier time than superficial glomerular podocyte injury during the progression of overt albuminuria in type 2 diabetic rats. Our data also support the hypothesis that the antialbuminuric effects of ARBs are associated with regression of superficial glomerular podocyte injury in type 2 diabetes with nephrotic-range albuminuria.
AB - Objective: Clinical studies indicate that the remission, regression or both of nephrotic-range albuminuria are exerted by angiotensin II receptor blockers (ARBs) in diabetes. The current study was performed to test the hypothesis that these effects of ARBs are associated with regression of glomerular podocyte injury. Methods: We examined the effects of an ARB, olmesartan, on glomerular podocyte injury in type 2 diabetic Otsuka-Long-Evans-Tokushima-Fatty rats with overt albuminuria. Results: At baseline (55-week-old), diabetic Otsuka-Long-Evans-Tokushima-Fatty rats showed severe albuminuria with desmin-positive areas (an index of podocyte injury) in both superficial and juxtamedullary glomeruli, and podocyte injury was much greater in juxtamedullary than in superficial glomeruli. At 75-week-old, Otsuka-Long-Evans-Tokushima- Fatty rats had developed more severe albuminuria and superficial glomerular podocyte injury, whereas juxtamedullary glomerular podocyte injury did not advance further. Olmesartan (10 mg/kg per day) decreased albuminuria and superficial glomerular desmin staining to levels that were lower than those at baseline, whereas advanced juxtamedullary glomerular podocyte injury was not changed. Conclusion: The current study demonstrates for the first time that juxtamedullary glomerular podocyte injury reaches a severe condition at an earlier time than superficial glomerular podocyte injury during the progression of overt albuminuria in type 2 diabetic rats. Our data also support the hypothesis that the antialbuminuric effects of ARBs are associated with regression of superficial glomerular podocyte injury in type 2 diabetes with nephrotic-range albuminuria.
KW - Otsuka-Long-Evans-Tokushima-Fatty rats
KW - angiotensin II receptor blockers
KW - juxtamedullary glomeuli
KW - olmesartan
KW - podocyte
KW - superficial glomeruli
UR - http://www.scopus.com/inward/record.url?scp=77958515296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958515296&partnerID=8YFLogxK
U2 - 10.1097/HJH.0b013e32833dfcda
DO - 10.1097/HJH.0b013e32833dfcda
M3 - Article
C2 - 20706133
AN - SCOPUS:77958515296
VL - 28
SP - 2289
EP - 2298
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 11
ER -